Oct 2 (Reuters) - Russia has signed manufacturing and supply agreements for its COVID-19 vaccine candidate with at least 10 countries in Asia, South America and the Middle East, as Moscow speeds up plans to distribute its shot abroad in the fight against the coronavirus. Russia was the first country to grant regulatory approval for a novel coronavirus vaccine, and did so before large-scale trials were complete, stirring concern among scientists and doctors about the safety and efficacy of the shot. It plans to conduct late-stage tests in more than 40,000 people and initial results are expected in October or November this year. VACCINE: The vaccine is being developed by Moscow's Gamaleya Research Institute and marketed by Russia's sovereign wealth fund, the Russian Direct Investment Fund (RDIF). Named Sputnik V in reference to the world's first satellite, and what Moscow sees as its success at becoming the first country to approve a coronavirus vaccine. The vaccine is administered in two doses and consists of two serotypes of a human adenovirus, each carrying an S-antigen of the new coronavirus, that enter human cells and produce an immune response. The platform used for the vaccine was developed by Russian scientists over two decades and had formed the basis for several vaccines in the past, including those against Ebola. TIMELINE: Russia plans to share preliminary results of its COVID-19 vaccine trial based on the first six weeks of monitoring participants. The first of 5,000 volunteers was vaccinated on Sept. 9, which means interim results could be issued some time after Oct. 21. Russia's sovereign wealth fund, which has invested in the vaccine's roll-out, has said it expects interim results to be published in October or November. Russia is aiming for the vaccine to be about 75% more effective than a placebo that is above the 50% threshold for COVID-19 vaccines set by the U.S. Food and Drug Administration. WHO'S GETTING THE VACCINE IN RUSSIA? The country launched a mass innoculation programme on Sept. 8, with plans to distribute it to teachers and medical workers etc. Putin and his daughter have taken it. DISTRIBUTION: About 400 people have been vaccinated so far under the mass innoculation programme. A government source told Reuters the interim Phase III trial results would likely inform a decision on whether to expand this mass inoculation drive, starting with people over 60. Russia expects to produce between 1.5 million and 2 million doses per month of its potential COVID-19 vaccine by the year end, gradually ramping up production to 6 million doses a month. TIE-UPS: RDIF said more than one billion people would receive Sputnik V in 2020-21. The following is a list of Russia's manufacturing, supply and clinical trial deals: MANUFACTURING DEALS REGION DOSES FUNDING FURTHER READING Brazil Not specified Not specified Paraná state, Unspecified no. of doses Not specified Brazil to be imported for tests; production for Brazil's market to begin in second half of 2021 Iran In talks Not specified India 300 mln Not specified SUPPLY DEALS REGION COMPANY/STATE DOSES DELIVERIES/TRIALS FURTHER READING India Dr Reddy's 100 mln Late 2020 Laboratories Mexico Landsteiner 32 mln Nov. 2020 Scientific Kazakhstan Not applicable 2 mln doses, could Not specified increase to 5 mln Uzbekistan Laxisam 35 mln Not specified Brazil Bahia state 50 mln 500 doses for trials expected in Nov. 2020 Egypt Pharco 25 mln Not specified Saudi Arabia Saudi Chemicals Not specified Not specified Nepal Trinity 25 mln Not specified Pharmaceuticals CLINICAL TRIALS REGION COMPANY/STATE TRIAL STAGE NUMBER OF FURTHER PARTICIPANTS READING India Dr Reddy's Late-stage 1,000-2,000 Belarus Not applicable Not Specified Not Specified Brazil Bahia state Late-stage 10,000 Mexico in talks Late-stage Not specified (Reporting by Vishwadha Chander, Dania Nadeem and Mrinalika Roy in Bengaluru; Editing by Anil D'Silva)
Our Standards: The Thomson Reuters Trust Principles.